169 related articles for article (PubMed ID: 37752419)
21. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
[TBL] [Abstract][Full Text] [Related]
22. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
24. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.
Javier R; Wang W; Drumm M; McCortney K; Sarkaria JN; Horbinski C
PLoS One; 2022; 17(2):e0257725. PubMed ID: 35134075
[TBL] [Abstract][Full Text] [Related]
26. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
27. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
[TBL] [Abstract][Full Text] [Related]
28. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
29. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Wang N; Wang F; Shan N; Sui X; Xu H
Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
[TBL] [Abstract][Full Text] [Related]
30. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
31. Status of IDH mutations in chondrosarcoma of the jaws.
You Z; Zhang J; Zhang H; Li X; Sun Z; Sun L
Int J Oral Maxillofac Surg; 2023 Jan; 52(1):26-31. PubMed ID: 35410781
[TBL] [Abstract][Full Text] [Related]
32. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
33. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
34. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract][Full Text] [Related]
35. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
36. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
Amary MF; Ye H; Forbes G; Damato S; Maggiani F; Pollock R; Tirabosco R; Flanagan AM
Virchows Arch; 2015 Feb; 466(2):217-22. PubMed ID: 25432631
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
Jin J; Hu C; Yu M; Chen F; Ye L; Yin X; Zhuang Z; Tong H
PLoS One; 2014; 9(6):e100206. PubMed ID: 24936872
[TBL] [Abstract][Full Text] [Related]
39. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
[TBL] [Abstract][Full Text] [Related]
40. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG; Grenert JP; Horvai A
Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
